Compare EXPD & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPD | GH |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 20.6B |
| IPO Year | 1995 | 2018 |
| Metric | EXPD | GH |
|---|---|---|
| Price | $181.77 | $160.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $133.00 | $119.79 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 4.02 | ★ 6.74 |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $6,920,948,000.00 | $982,021,000.00 |
| Revenue This Year | $2.71 | $33.30 |
| Revenue Next Year | $3.74 | $28.27 |
| P/E Ratio | $99.51 | ★ N/A |
| Revenue Growth | 13.49 | ★ 32.88 |
| 52 Week Low | $113.06 | $43.66 |
| 52 Week High | $183.52 | $176.58 |
| Indicator | EXPD | GH |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 58.88 |
| Support Level | $157.54 | $152.64 |
| Resistance Level | $183.52 | $174.08 |
| Average True Range (ATR) | 4.03 | 8.19 |
| MACD | -0.95 | -0.21 |
| Stochastic Oscillator | 62.65 | 51.65 |
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2025, Expeditors derived 36% of consolidated gross revenue from airfreight, 25% from ocean freight, and 39% from customs brokerage and other services.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.